Yahoo Finance • last month
Adam Dubow, General Counsel & Secretary of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN), sold 4,365 shares of common stock on August 18, 2025, at a weighted average price of $6.7671, for a total value of $29,538. The prices for these sha... Full story
Yahoo Finance • 2 months ago
Day One Biopharmaceuticals (NASDAQ:DAWN) reported a robust financial performance for the second quarter of 2025, driven by strong revenue growth and strategic expansions. The company’s stock experienced a 2.15% increase in aftermarket trad... Full story
Yahoo Finance • 2 months ago
DAY ONE BIOPHARMACEUTICALS INC (NASDAQ:DAWN [https://www.chartmill.com/stock/quote/DAWN/profile]) REPORTS Q2 2025 EARNINGS: REVENUE GROWTH BUT WIDER-THAN-EXPECTED LOSS Day One Biopharmaceuticals Inc released its second-quarter 2025 financ... Full story
Yahoo Finance • 2 months ago
BRISBANE, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages... Full story
Yahoo Finance • 4 months ago
Dr. Michael Vasconcelles brings more than 25 years of extensive oncology research, development and health technology expertise and corporate executive leadership to Day One Dr. Vasconcelles to drive pipeline creation and execution BRISBA... Full story
Yahoo Finance • 5 months ago
OJEMDA™ (tovorafenib) prescriptions grew 16% in Q1 2025 compared to Q4 2024 Achieved Q1 2025 OJEMDA™ (tovorafenib) net product revenue of $30.5 million Ended the first quarter with $473.0 million in cash, cash equivalents and short-term... Full story
Yahoo Finance • 5 months ago
BRISBANE, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all age... Full story
Yahoo Finance • 7 months ago
Achieved Q4 2024 and full year 2024 OJEMDA™ (tovorafenib) net product revenues of $29.0 million and $57.2 million, respectively Ended 2024 with $531.7 million in cash, cash equivalents and short-term investments Company to host conferenc... Full story
Yahoo Finance • 2 years ago
BRISBANE, Calif., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for peo... Full story
Yahoo Finance • 2 years ago
BRISBANE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for peo... Full story
Yahoo Finance • 2 years ago
PHILADELPHIA, Nov. 11, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) (“Day One”) on behalf of the company’s investors. Since February 2023, shares of Day One’... Full story
Yahoo Finance • 2 years ago
STAMFORD, Conn., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Abbott Cooper PLLC is investigating Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”) on behalf of the Company’s investors. The investigation seeks to determi... Full story
Yahoo Finance • 2 years ago
NDA for tovorafenib in relapsed or progressive pLGG accepted for FDA priority review PDUFA target action date of April 30, 2024 BRISBANE, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or... Full story
Yahoo Finance • 2 years ago
In this article we present the list of 12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds. Click to skip past our discussion of the biotech space and straight to the 5 Best Small-Cap Biotech Stocks with Massiv... Full story
Yahoo Finance • 2 years ago
BRISBANE, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for peo... Full story
Yahoo Finance • 2 years ago
Overall response rate (ORR) greater than 50% across three assessment criteria Median duration of tovorafenib treatment of 15.8 months as of June 5, 2023, with 66% of patients remaining on treatment FDA filing decision expected by mid-Nov... Full story
Yahoo Finance • 2 years ago
Day One receives an exclusive license to develop and commercialize small molecule drug candidates for pediatric and adult cancers with high unmet need Collaboration augments Day One’s portfolio of targeted therapies in oncology BRISBANE,... Full story
Yahoo Finance • 2 years ago
BRISBANE, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with li... Full story
Yahoo Finance • 2 years ago
FIREFLY-1 clinical abstract selected for oral presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting Leadership team strengthened with executive appointments in clinical development and commercialization Pre... Full story
Yahoo Finance • 2 years ago
New clinical data from registrational FIREFLY-1 study to be featured as an oral presentation Trial-in-progress poster from FIREFLY-2 andhealthcare resource use for pediatric low-grade glioma care poster to be presented Company to host co... Full story